1,918 results on '"Giaccone, Giuseppe"'
Search Results
52. Figure S1 from Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors
53. Table S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
54. Supplementary Data from Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib
55. Figure S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
56. Supplementary Table 1, Supplementary Figures 1-4 from A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations
57. Supplementary Figure Legend from Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors
58. Supplementary Materials and Methods from Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
59. Supplementary Figure 2 from Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors
60. Data from Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
61. Supplementary Table 1, Figures 1 - 2 from The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo
62. Supplementary Methods, Figures 1-2 from A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
63. Supplementary Methods from 18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors
64. Supplementary Figure 1 from Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors
65. Data from Heat Shock Protein 90-Sheltered Overexpression of Insulin-Like Growth Factor 1 Receptor Contributes to Malignancy of Thymic Epithelial Tumors
66. Supplementary Data from Heat Shock Protein 90-Sheltered Overexpression of Insulin-Like Growth Factor 1 Receptor Contributes to Malignancy of Thymic Epithelial Tumors
67. Data from Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors
68. Data from An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer
69. Supplementary Methods, Figures 1-3, Tables 1-5 from A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
70. Supplementary Figures 1-3, Tables 1-6 from Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer
71. Legends of supplementary figure 1 and 2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
72. Supplementary Figure S1 from Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival
73. Supplementary Figure/Table Legends from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
74. Supplementary Data from Role and Relevance of TrkB Mutations and Expression in Non–Small Cell Lung Cancer
75. Supplementary Figure 3 from Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors
76. Supplementary Figures 1-4, Table 1 from Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
77. Data from MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non–Small Cell Lung Carcinoma
78. Supplementary Figure 1 from MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non–Small Cell Lung Carcinoma
79. Supplementary Tables 1-9 from MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non–Small Cell Lung Carcinoma
80. Supplementary Appendix 1 from MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non–Small Cell Lung Carcinoma
81. High-Risk Non-Small Cell Lung Cancer Treated With Active Scanning Proton Beam Radiation Therapy and Immunotherapy
82. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
83. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
84. Apoptosis Pathways and New Anticancer Agents
85. Contributors
86. Humoral and Cellular Immune Dysregulation and Lung Cancer
87. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial
88. Reply to Dr. Goto’s Letter: “A Thymoma Mouse Model Harboring a Gtf2i L424H Mutation”
89. Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
90. Molecular Pathways of Drug Resistance
91. Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions
92. Topoisomerase I Inhibitors: Current Use and Prospects
93. Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials
94. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials
95. Sex and cancer immunotherapy: Current understanding and challenges
96. The regulation of CD73 in non-small cell lung cancer
97. Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
98. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
99. Platinum Compounds in Lung Cancer: Current Status
100. An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.